Two Factorial Randomized Clinical Trial comparing dose and timing of estrogen supplementation on the prevention of athersclerotic cardiovascular disease in post menopausal women

Student ID: 997900158

March 9, 2013

Abstract

1   Introduction

Athersclerotic cardiovascular disease is an important cause of cardiovascular dissease in post-menopausal women. In 1994, Cardiovascular disease killed a half million women and accounted for over 40% of all deaths in women, more than all forms of cancer combined[1]. Even though there has been an overall decline in the death rate due to cardiovascular disease in the United States over several decades, the rate of decline is less for women and especially african-american women [2]. While men are more commonly affected by cardiovascular disease, risk increases rabpidly in women as they age, doubles every decade after age 55[3]. It has been shown that reduced circulating ostradiol during menopause increases atherogenic lipids and reduces carotid blood flow, causing increased incidence of athersclerotic cardiovascular dis-

ease [4]. Menopause is the abcence of a menstural cycle in the previous 12 months, and occurs at an average age of 51 but can range between 45 and 55 years [5]. Supplamental oestrogen has been used for some time to treat symptoms of menopause and its associated increase in athersclerotic cardiovascular disease risk, however serious side effects (higher risk of breast cancer, increased blood clots and endometrial cancer) have been documented [5]. Recent research has also questioned the cardiovascular protection associated with menopausal hormonal therapy and concluded no overall benfit to supplamental estrogen overall, and a possible interaction between time of therapy initiation and protection provided [6, 7]. Since the initial reasearch questioning the efficacy of menopausal hormonal therapy was completed, there have been numerous innovations in the form and dose of estrogen deliverey have occurred, and it is hypothesised that these new forms/dosing regiemes may provide improved protention.

This two-by-two factorial radomized clinical trial is designed to assess the effects of intiating estradiol supplementation at diffent doses and different times following the onset of menopause on the risk of athersclerotic cardiovascular disease. The study Hypothesis is that initiating estrogen therapy before the onset of menopause is protective of athersclerotic cardiovascular disease, and that a reduced dose of estrogen provides the same protection with reduced side effects.

2 Methods

The study population was drawn from women presenting to Kaiser Permanente between 2000-01-01 and 2009-12-31, between the ages of 40 and 50 that were undergoing signs of peri-menopause (last cycle less than 12 months ago, but no regular monthly cycle). Kaiser Permanente is a managed care consortium based in northern California. It has almost 15,000 physicians operating in 650 facilities spread over 9 states, and serves nearly 9 million members [8]. On identifying a possible study subject, a full physical examination and medical history was taken, and where possible validated with a central database of historical medical records maintained by Kaiser Permanente. During this physical examination BP, BMI, race, and age were measured, and lifdestyle factors such as smoking and phjysical activity levels recorded. Blood was also collected during this initial examination and levels of lipoprotiens measured. Any woman with a previous hysterectomy, had taken estrogen suppleaments in the past, or had experienced any prolonged angina was disqualified from the study as hysterectomy causes instant menopause at any age, and angina may be a sign of preexisting heart conditions.

Sample size recquirements were calculated using epi-info with a subclinical athersclerotic cardiovascular disease rate of 25% Interim analysis were completed at bi-yearly intervals by an independent data and safety monitoring comitee, and the decision to procedd based on participant safetey (no increased rates of side effects or athersclerotic cardiovascular disease) and the percieved benefit of continuing with study. OBrien-Flemming spending

strategy was used to generate stopping boundaries for each planned analysis.

Two factorial design was chosen to allow simountaneus comparison of dose and timing effects, and the use of a very large sample size allowed the assessment of interactions at sufficeint power. The two dose levels chosen were 0.625mg and 0.3mg of conjugated equine estrogens, delivered per os. 0.625 mg SID PO is the standard therapy currently in use, the lower dose of 0.3mg has been suggested as a way to maximise benefit (menopause symptoms, CVD,osteoporosis), while minimising harmful side effects (cancer risk, blood clots) associated with estrogen. The two timing levels chosen were initiation of therapy during peri menopause, or initiation 3 years after menopause. The use of a two factorial design resulted in 4 study groups, as described in figure1.

Patients were randomised using a centralised allocation procedure, with both patient and physician blinded to allocation method. After eligibility was established, an auto generated email containing patient information was sent to a server maintained in the researchers office at Kaiser Permanente's headquarters in Oakland, California. This computer used a schedule of random numners generated from open radio freqency atmoshperic noise [9] and study participants were allocated to one of the four groups basd on this number. The allocation, general patient details, and source and timsetamp of the allocation request were recorded and compared to doctors own records of assignment to ensure accuracy. The result of this allocation was returned to the physician in an email with a number 1-4 and the appropriate treatment initiated.

Following assignment, all patients recieved a 6 month supply of pills,

regardless of group assignment. This pill pack was in nondescript packaging, with only a number label, and was renewed every 6 months by mail from Kaiser Permanente headquarters. Even after assignment, the sequence and allocation was concealed from study participant and physician. Those that were assigned late deliverey of either dose were initially given sugar pills that had same appearance, taste, and smell as the real estrogen pills. 3 years after menopause was determined to have taken place (more than 12 months amenorrhoea) had their next 6 monthly supply of pills converted to estrogen, at a dose depending on their assignement. Again there was no way to tell the difference between pills having different doses.

Patients had annual checkups with their Kaiser Permanente physician during the study period. During this examination, a standard examination and history was performed, as well specific questions relating to the onset of menopause, symptoms experienced during the year, and any incidence of angina or clinical cardiovascular disease. Side effects of estrogen therapy monitored included cancer (breast, colon, endometrial), and clotting events (Deep Vein Thrombosis, Ischaemic stroke) All women had their responses checked against actual medical history, improving accuracy of data and minimising recall bias. To assess the progression of subclinical athersclerotic cardiovascular disease, women had a carotid ultrasound to measure carotid arterey intima-media thickness. The thickness of carotid arterey intima-media was recorded and compared to previous measurements to assess disease progression. This intervention was well tolerated as women were presenting to their health professional for an annual checkup anyway, and the Carotid ultrasound is quick and non-invasive In addition, the quality

of these measurments were maintained by using a trained ultrasonographer at each of the Kaiser Permanente facilities. Before the beginnning of enrollment, these ultrasonographers were trained at a central location on a standard protocol for taking measurements, and the inter-observer agreement assessed by completing an examination of 5 test subjects.

All patients were thoroughly briefed on the study design and interventions, and signed informed consent and liability release forms.

2.1 Statistical Evaluation

The primary study endpoint was progression of subclinical athersclerotic cardiovascular disease defined as an increase in carotid inter-media thickness of more than 0.0035mm per year diagnosed on carotid ultrasound. A second study endpoint was clinical athersclerotic cardiovascular disease, which included stroke, congestive heart disease, and death due to cardiac causes.

Kaplan-Meier survival curves for overall survival were compared by log-rank test, and the unadjusted HR (and 95% CI) was calculated using a Cox regression analysis. As a secondary analysis, potential covariates (race, age, smoking, physical activity levels) were included in the Cox regression model to generate an adjusted HR for overall survival.

All analysis was completed on an intention to treat basis, and all statistical analysis were completed in R [10] on data that had a random hashing algorithm performed before analysis, ensuring blinding of statistitians.

3 Results

43,426 women were intially enrolled in this study, with 42,236 assigned to a treatment group and 38,234 completing and were analysed in the study (As shown in the flow Baseline characteristics of study participant can be seen in table1.

The incidence of side effects that can be caused by estrogen is shown in table2, Comparison rates in post menopausal women not undergoing menopausal hormonal therapy are shown for comparison. As can be seen from table2, ther eis no increased risk of side effects associated with menopausal hormonal therapy.

The compliance rate among study participants was assesed by measuring estrogen levels in blood of a sample (n=100) of participants recieving estrogen at least 2 years following menopause. Compliance was found to be good, at 93%, and no adjustment was made for those found to be non compliant.

The rates of diagnosis on each ultrasonographer were compared to ensure inter-observer agreement. As each ultrasonographer completed many measurements, each individual observer distribution was compared to the average distribution of all observers, to determine if any one observer was over or under measuring carotid inter-media thickness. The interobserver correlation was above 90% and no single observer consistently over or under measured carotid inter-media thickness. The measuremnents between ultrasonographers were compared

4 Discussion

4.1 Strengths and Limitations

Data quality was a strenth of this study. Cross validating the patients oral medical histories with the actual recorded histories from the Kaiser Permanente central databases ensures accuracy and reduces recall bias. Allocation of participants to study groups was entirely random and repeatable, and the comparison of allocation and actual treatment records allowed analysis to be undertaken on an accurate intention to treat basis.

The triple blinding methods used in this study were also a strength, with study participants, consulting physicians, and statistitians all unaware of which group participants/data were assigned to.

A potential limitation of this study was the selection of study participants from Kaiser Permanente hopitals. Rates of insurance are correlated with Socio economic status and Education level, both factors that are also associated with use of menopausal hormonal therapy. There may be some relationship between lifestyle factors/SES and progression of athersclerotic cardiovascular disease, and out attemp to control for these factors (correcting for smoking and activity levels) may be insufficient.

Another potential limitation is the loss of blinding to study participants based on the effects of treatment. Some women experience bleeding when taking an estrogen supplement, and this would remove blinding.

5 Figures

| | 43,426 | | | | | considered for enrollment |
| | 42,236 | | | | | 97% assigned to treatment group |

	Group 1 low:early	Group 2 low:late	Group 3 high:early	Group 4 high:late	total	
number	10552	10563	10559	10562	42236	100% assigned
percent	24.98%	25.01%	25.00%	25.01%	100.00%	
received intended Rx	10451	10462	10468	10442	41823	99% received intended Rx
	24.99%	25.01%	25.03%	24.97%	100.00%	
completed study	9557	9561	9564	9552	38234	91% completed study
	25.00%	25.01%	25.01%	24.98%	100.00%	
analysed	9557	9561	9564	9552	38234	100% analysed
	25.00%	25.01%	25.01%	24.98%	100.00%	

Figure 1: Flow Diagram showing study participant allocation

	Characteristic	Number				
		Group 1 low:early	Group 2 low:late	Group 3 high:early	Group 4 high:late	
Demographic	age, median	51.30	50.90	51.20	50.98	
	%smoke	21%	23%	20%	22%	
	% > 3hr physical activity/wk	15%	16%	14%	15%	
	% african american	12%	14%	13%	12%	
Medical	BP, systolic mean	103.00	105.00	101.00	107.00	
	BMI	24.00	25.00	27.00	24.00	
	% high LDL	8%	7%	6%	7%	
	months since last cycle, mean	18.00	17.00	15.00	19.00	
	total	10552	10563	10559	10562	42236

Figure 2: Characteristics of study participants.

		Number				
		Group 1 low:early	Group 2 low:late	Group 3 high:early	Group 4 high:late	Gen.pop
	Side Effect					
Cancer	Breast	10	12	17	15	16
	Colon	22	26	18	21	24
	Endometrial	36	32	38	33	34
Clotting	Deep Vein Thrombosis	27	29	31	26	28
	Ischaemic stroke	52	54	48	49	50
	Congestive heart disease	68	72	70	71	69
	Death due to cardiac causes	106	108	110	107	105
	total	10552	10563	10559	10562	42236

Figure 3: Incidence of Side effects in study groups

```
C:\ C:\PROGRA~1\EPI_INFO\STATCALC.EXE                                    _ □ X
    EpiInfo  Version  6              Statcalc              November  1993

    Unmatched Cohort and Cross-Sectional Studies (Exposed and Nonexposed)
           Sample  Sizes  for  4.00 %  Disease  in  Unexposed  Group

                          Disease     Risk   Odds         Sample  Size
Conf.      Power    Unex:Exp  in Exposed  Ratio  Ratio   Unexp.   Exposed    Total
95.00 %   80.00 %     1:1      7.69 %    1.92   2.00      686      686      1,372

90.00 %      "         "                                  551      551      1,102
95.00 %      "         "         ┌─────────────────┐      686      686      1,372
99.00 %      "         "         │ Change  values for│     995      995      1,990
99.90 %      "         "         │ inputs  as desired,│  1,431    1,431    2,862
95.00 %   80.00 %      "         │ then  press F4 to │     686      686      1,372
   "      90.00 %      "         │ recalculate.     │      900      900      1,800
   "      95.00 %      "         └─────────────────┘    1,100    1,100    2,200
   "      99.00 %      "                                1,532    1,532    3,064
   "      80.00 %     4:1                               1,588      397      1,985
   "         "        3:1                               1,290      430      1,720
   "         "        2:1                                 988      494      1,482
   "         "        1:2                                 532    1,064      1,596
   "         "        1:3                                 480    1,439      1,919
   "         "        1:4                                 453    1,813      2,266

   F1-Help                        F5-Print     F6-Open  File     F10-Done
```

Figure 4: Sample size function and calculation output from R. Calculations agrees with Epi Info when continuity correction was applied.

References

[1] AHA. *1997 Heart and Stroke Facts: Statistical Update.* American Heart Association, Dallas, TX, 1997.

[2] L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T. Manolio, and E. Barrett-Connor. Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association. *Circulation*, 96(7):2468–2482, October 1997.

[3] T Gordon and WB Kannel. Menopause and coronary heart disease. The Framingham Study. *Annals of internal . . .*, 1978.

[4] Howard N Hodis and Wendy J Mack. Atherosclerosis Imaging Methods : Assessing Cardiovascular Disease and Evaluating the Role of Estrogen in the Prevention of Atherosclerosis. *American journal of cardiology*, 9149(02):19–27, 2002.

[5] Gold, Kass, and Stuckey. MPM406 ass 3 description. pages 1–3, 2012.

[6] GL Anderson and MC Limacher. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA: the journal of . . .*, 2004.

[7] Ross L Prentice, Joann E Manson, Robert D Langer, Garnet L Anderson, Mary Pettinger, Rebecca D Jackson, Karen C Johnson, Lewis H Kuller, Dorothy S Lane, Jean Wactawski-Wende, Robert Brzyski, Matthew Allison, Judith Ockene, Gloria Sarto, and Jacques E Rossouw. Benefits and risks of postmenopausal hormone therapy when it is

initiated soon after menopause. *American journal of epidemiology*, 170(1):12–23, July 2009.

[8] Chris Rauber. Kaiser to cut 1,200 jobs in Northern California - Sacramento Business Journal, 2009.

[9] Dirk Eddelbuettel. *random: True random numbers using random.org*, 2009.

[10] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2012.